Hikma Pharmaceuticals Share Discussion Threads

[isstaaz] 01/2/2018 10:11

Way oversold. JPM & co are targeting process and people costs, which are the bulk of healthcare costs. Pharma costs are a small %age

[bantam175] 31/1/2018 09:40

JPM, Hathaway and amazon news a downwer

[r ball] 23/1/2018 08:58

You can also count on Deutsche bank to be a contra indicator.....

[karateboy] 20/1/2018 19:12

Twice HIK bounced back from 950p. Hopefully share price remains above 950p until the update in March.

[karateboy] 12/1/2018 09:50

Full year result for 2017 to be announced on 14 March 2018. Trading update on 9th November 2017 was very positive. There is an issue beyond company's control is the devaluation of Egyptian pound. It was devalued in November from 8.8 to 17.6. So currently 17.6 Egyptian pounds buys you one USA dollar. This is good in one hand if your earning is in USA $, but makes goods produced in Egypt expensive ....I hope the company stops the share price drift south by updating the market befor 14th of March with some good news such as progress with PROGRESS with FDA submission.

[richrost] 12/1/2018 08:54

If its any consolation, I was holding AAL when they dropped to £2.20 and were
ranked as junk status. today they are sitting at £17.54.
OK its a different sector, but you never know.

[bobogyo] 11/1/2018 19:06

What are your thoughts on the outlook for this to keep? I bought back then it was 16 so was thinking if I should cut losses or wait out for better times? Is it worth to wait at all? Thanks

[bantam175] 10/1/2018 08:59

No worries then. Just flapping their lips to feel the breeze.

[soniraman] 10/1/2018 08:43

Jeffries downgrades to underperform : 894

[mrthomas] 02/1/2018 15:34

Would buy This if it gets below 11as people have said strong balance sheet should make a profit reasonly good cash flow

[death by donut] 19/12/2017 20:28

Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa

London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima(TM) (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima(TM) (rituximab), Remsima(R) (infliximab) and Herzuma(R) (trastuzumab) - in all its MENA markets.

Truxima(TM) is mAb biosimilar to Roche's MabThera(R) (rituximab), which is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima(TM) (rituximab) in all of its MENA markets, leveraging Hikma's strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise.

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "We are pleased to be adding Truxima(TM) to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines."

[suetballs] 19/12/2017 16:26

Do I detect a pulse?
Suet

[r ball] 15/12/2017 05:59

Treva cutting 25% of workforce? I wonder what Indian firms are doing? Industry shake out?

[justiceforthemany] 13/12/2017 12:45

Another new product announced today to boost earnings and profits

[broadwood] 08/12/2017 16:27

Is this finally the start of the great fightback?

[hickool] 05/12/2017 09:12

Was a mistake to buy this at £13.50. Low debt and healthy b/sheet so will hold for a while.

[justiceforthemany] 04/12/2017 19:37

H2 tends to be far stronger than H1. share price drop way overdone IMO as H1 2017 was no worse than H1 2016. After another drop today worst case this is trading on a P/E of just 12. Great balance sheet also.

[r ball] 20/11/2017 17:35

If fda settlement was sorted I would expect share price of £25. The main issue is Indian access to us generics market.

[justiceforthemany] 20/11/2017 14:31

Check the reports pye. When the share price dropped to 9 the forward P/E was 10.

[bantam175] 20/11/2017 14:06

Well it took 9 months to get down here, how long to get back I wonder?

Settlement with FDA on the cards maybe? Given current rise.

Time will tell as always.

[pyemckay] 19/11/2017 18:43

justice- stop posting incorrect data. This is not on a pe of 10.

[suetballs] 16/11/2017 10:41

Gosh - could it be a blue day?
Suet

[justiceforthemany] 14/11/2017 15:29

Core earnings for this year are expected to be flat on 2016 at 118.5c/91p. A P/E of 10 is far too low for this sector and a company with a great balance sheet. Numis target of 1300p seems fair. Peel Hunt going for 1390p. Current share price of 950p is ridiculous and shorter driven.
HIK Peel Hunt Hold 949.50 960.50 - *1,390.00 Target Price*

[citytrader66] 14/11/2017 08:30

got some at 913.2p. had quote for lower but didn't take it then couldn't buy for a minute. always the same at the bottom.